Supersonic Imagine : SuperSonic Imagine : SuperSonic Imagine Announces a Significant Financing Round - 28 million euros raised -

   Supersonic Imagine : SuperSonic Imagine : SuperSonic Imagine Announces a
Significant Financing Round - 28 million euros raised - FSI subscribes to half
        the round alongside historical investors and two new arrivals

          SuperSonic Imagine Announces a Significant Financing Round

                           28 million euros raised
                       FSI subscribes to half the round
             alongside historical investors and two new arrivals

Paris, April 3^rd 2013,  SuperSonic Imagine, a  French ultrasound company,  is 
pleased to announce that it  has raised €28million with €14million  invested 
by the FSI (French Investment Fund)  alongside two new investors, Alto  Invest 
and KLSC (Kuwait Life  Sciences Company) and  a substantial subscription  from 
the company's historical investors.

Edmond de  Rothschild  Investment  Partners, Auriga  Partners,  Omnes  Capital 
(formerly Crédit  Agricole Private  Equity), CDC  Entreprises, NBGI  Ventures, 
Wellington Partners, iXO Private Equity, and Mérieux Développement, along with
Alto Invest and KLSC, are subscribing to €14 million.

SuperSonic Imagine will invest the funds to accelerate international sales and
marketing of  its Aixplorer®  ultrasound device,  a product  which  originally 
targeted women's health when it was launched in 2009, but which now covers all
fields of general radiology, with regulatory approval in all key international

Aixplorer's competitive  advantages  include  exceptional  image  quality  and 
unique technologies  such  as: ShearWave(TM)  Elastography  and  UltraFast(TM) 
Doppler. ShearWave  Elastography  is  the  only  modality  available  on  any 
ultrasound product which is able to detect tissue stiffness in a  reproducible 
and quantifiable manner. UltraFast Doppler, is unique in its ability to image
blood flow up to ten times  faster than conventional color Doppler. This  not 
only  provides  more  reliable   diagnoses  for  the   patient  but  it   also 
significantly accelerates workflow for the practitioner.

As a result  of the expansion  of its addressable  market, SuperSonic  Imagine 
registered strong growth in 2012 with  a turnover of €14million, up 40%  from 
the previous year, 80% of which came from international.

"Currently certified in 54 countries and with more than 500 units sold around
the globe, Aixplorer is a worldwide success. This new injection of funds  will 
allow us  to  take  a  leap  forward in  our  commercial  development  with  a 
particular focus on  the booming Chinese  market," explained Jacques  Souquet, 
founder and CEO of SuperSonic Imagine.

"The FSI sees SuperSonic Imagine as a company with considerable potential for
growth based on  revolutionary technological innovation  that had its  origins 
from a successful technology  transfer from top  research institutions into  a 
great start up company. The FSI  is pleased to provide SuperSonic Imagine  the 
funding it  needs  to pursue  both  its business  and  scientific  development 
worldwide," said Mailys Ferrere, Director of Investment at the FSI and  member 
of the FSI Executive Board.

Claude Cohen-Bacrie Executive VP & CTO of SuperSonic Imagine added that  "This 
investment will help us  remain at the forefront  of scientific and  technical 
innovation and affirm our clinical position through new research." 

Currently, there is data from more  than fifty clinical trials that prove  the 
benefits of  ShearWave  Elastography  in improving  ultrasound  diagnoses  for 
various diseases  including  breast  cancer, prostate  cancer,  chronic  liver 
disease, muscular disorders, thyroid nodules, and many more.

Abdominal, gynecological  and  pediatric imaging  are  also available  on  the 
Aixplorer, and the results appear very promising.

Vascular imaging, launched in 2011 with UltraFast Doppler, has also been  very 
successful. Aixplorer's UltraFast Doppler is the only Doppler able to  combine 
Color Flow Imaging with Pulsed Wave  Doppler in a single ultrasound mode.  The 
technology produces a complete vascular analysis in just a few seconds with an
unrivalled level of detail, improving the examination procedure and  providing 
more reliable diagnoses.

Gordon Waldron, Executive VP  and CFO of SuperSonic  Imagine, is pleased  with 
this new investment which  is among the most  significant private fundings  in 
the French healthcare sector in recent  years. He added, "Since inception,  we 
have been primarily R&D focussed as SuperSonic brought the first innovation to
the ultrasound space in the past 20 years. Aixplorer has now become a  mature 
system with  a range  of applications  that  meet the  needs of  both  general 
imaging experts and their patients.  Consequently, we will use these  proceeds 
to increase  our sales  and marketing  footprint as  we enter  the growth  and 
execution phase of our development».


About SuperSonic Imagine
Founded in 2005 and based  in Aix-en-Provence (France), SuperSonic Imagine  is 
an  innovative,  international  company  specializing  in  ultrasound  medical 
imaging. The company designs, develops, and markets a revolutionary ultrasound
system, Aixplorer®,  with  a  unique  ultrasound  imaging  technology,  called 
MultiWave(TM) Technology. This  technology allows  Aixplorer® to  be the  only 
ultrasound system  that  images two  types  of waves  to  better  characterize 
tissue; an ultrasound  wave to  ensure impeccable  image quality  and a  shear 
wave, ShearWave(TM) Elastography, to compute and display true tissue stiffness
in real time  by acquiring images  nearly 200 times  faster than  conventional 
In 2009, SuperSonic Imagine was granted 510(k) clearance by the Food and  Drug 
Administration in the United States and CE mark in Europe for the marketing of
Aixplorer®.  Distribution  agreements  have   been  signed  with   prestigious 
companies such as Hologic (Nasdaq : HOLX) for the breast market in the  U.S.A. 
and Canon (NYSE :  CAJ) for Japan.  SuperSonic Imagine's distribution  network 
has now more than 35 partners worldwide.

About French Investment Fund
FSI is a public limited company, 51% held by The Caisse des Dépôts group,  and 
49% held by  The French State.  As a  prudent investor, FSI  holds a  minority 
stake into  French  private  companies that  build  valuable  and  competitive 
strategies increasing French business opportunities.
More information to come on

About BPI France
OSEO, CDC Entreprises and French Investment  Fund will go forward as a  single 
company, BPI France, known as French Public Investment Bank, as soon as merger
requirements, such as European Commission  Compliance and Regulation, will  be 
fully integrated.  This  institution  will  offer a  broad  range  of  funding 
solutions, debt instruments as  well as equity's, not  only dedicated to  SMEs 
and innovative companies but also to large-scale companies that foster  French 
economic growth from a strategic perspective.
More information to come on

ALTO INVEST is an independent  management company dedicated to investments  in 
SMEs. ALTO INVEST manages over € 300 million in retail and institutional funds
(FCPI, FIP  and FCPR),  invested  in more  than 100  European  innovation-rich 
companies representing a total turnover of € 6 billion and 40,000 employees.
Alto Invest is fully  approved by the  French financial authorities  (Autorité 
des Marchés Financiers) and is an active member of the French Asset Management
Association (Association Française de la Gestion Financière).

About KLSC
Kuwait Life  Sciences Company  (KLSC) is  fully owned  by National  Technology 
Enterprises Company (NTEC);  a Kuwait Investment  Authority (KIA) fully  owned 
company. KLSC aims to  accelerate the transfer  of best in-class  technologies 
and innovative business models practiced globally to match the needs of Kuwait
&  the  region,  in  addition   to  offering  healthcare  professionals   with 
distinguished  opportunities   for   development   and   growth   that   match 
international  standards.  To   achieve  this,  KLSC   looks  for   investment 
opportunities in the areas of medical technology, diagnostics, pharmaceuticals
and healthcare services which address  prevalent diseases in the MENA  region. 
KLSC  also  has  a  distribution  arm  to  commercialize  innovative   medical 
technologies mainly  in laboratory  diagnostics, surgical  & Imaging,  mobile 
Health and screening programs. With regards to professional development,  KLSC 
has established  the  first healthcare  academy  in the  GCC  region  offering 
continuous medical education programs across all healthcare sectors.

For further information, visit the KLSC website at

                                Press contacts

SuperSonic Imagine                  H&B Communication              Anne Hardy
Michele Debain                      Florence Portejoie   
Global Marketing Director  +33 (0)1 58 18 32 51 +33 (0)1 58 18 32 58           +33 (0)6 13 56 23 96
+33 (0)4 42 99 24 32                +33 (0)6 88 84 81 74

Anne Descamps                 Elise Hermant
Havas Worldwide               Havas Worldwide
+33 (0)1 58 47 93 32          +33 (0)1 58 47 84 09

Alto Invest:
Samuel Beaupain
+33 (0)1 80 81 50 05

Fatma AlGharabally
Investment Manager
Tel:(+965) 22 49 09 69
Cell: (+965) 99 44 50 80

Press release


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Supersonic Imagine via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.